DE2759297B1 - Process for the preparation of 2-oxo-1-pyrrolidine-acetamide - Google Patents

Process for the preparation of 2-oxo-1-pyrrolidine-acetamide

Info

Publication number
DE2759297B1
DE2759297B1 DE2759297A DE2759297A DE2759297B1 DE 2759297 B1 DE2759297 B1 DE 2759297B1 DE 2759297 A DE2759297 A DE 2759297A DE 2759297 A DE2759297 A DE 2759297A DE 2759297 B1 DE2759297 B1 DE 2759297B1
Authority
DE
Germany
Prior art keywords
oxo
pyrrolidine
acetamide
amide
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2759297A
Other languages
German (de)
Other versions
DE2759297C2 (en
Inventor
Slobodan Dr Djokic
Branimir Dr Gaspert
Alfred Dr Maasboel
Branimir Simunic
Mirjana Dipl-Ing Tomic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karl O Helm AG
Pliva Farmaceutika dd
Original Assignee
Karl O Helm AG
Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from YU7776A external-priority patent/YU39660B/en
Priority claimed from YU198376A external-priority patent/YU40148B/en
Application filed by Karl O Helm AG, Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd filed Critical Karl O Helm AG
Publication of DE2759297B1 publication Critical patent/DE2759297B1/en
Application granted granted Critical
Publication of DE2759297C2 publication Critical patent/DE2759297C2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

Es ist bekannt, daß das 2-Oxo-i-pyrrolidin-acetamid durch Reaktion von 2-Oxo-pyrrolidin-Na (hergestelk aus 2-Oxo-pyrrolidin und Na oder NaOtI) mit 2-ChIoracetamid, ferner durch Einwirken von NH3 adf 2-Oxo-l-pyrrolidin-essigsäureester oder -chlorid (GB 10 39 113) oder durch thermische Zersetzung Sires Ammoniumsalzes (GB 13 09 692) hergestellt werden kann. Die erwähnte Verbindung zeigt beispielsweise therapeutische Wirkung bei der Behandlung chronischer Störungen der Gehirnfunktion. Sie ist bekannt unter dem ,genetische» Namen Pyracetam.It is known that 2-oxo-i-pyrrolidine-acetamide is produced by reaction of 2-oxo-pyrrolidine-Na (produced from 2-oxo-pyrrolidine and Na or NaOtI) with 2-chloroacetamide, and also by the action of NH 3 adf 2-Oxo-1-pyrrolidine-acetic acid ester or chloride (GB 10 39 113) or by thermal decomposition of Sires ammonium salt (GB 13 09 692) can be prepared. The compound mentioned shows, for example, a therapeutic effect in the treatment of chronic disorders of the brain function. It is known by the "genetic" name pyracetam.

Es wurde nun gefunden, daß die Verbindung der Formel 1 auf einfache Weise entsprechend dem folgenden Reaktionsschema hergestellt werden kann:It has now been found that the compound of formula 1 in a simple manner according to the the following reaction scheme can be produced:

2H2N-CH2-CONH2 + (H)2H 2 N-CH 2 -CONH 2 + (H)

(IH)(IH)

ClCH2 -CH2 -Ch2-CONH-CH2-CONH2 (IV)ClCH 2 -CH 2 -Ch 2 -CONH-CH 2 -CONH 2 (IV)

HCl H2N-CH2-CONH2 HCl H 2 N-CH 2 -CONH 2

(V) i (V) i

CH2CONH2
(H
CH 2 CONH 2
(H

Erfindungsgemäß wird Glycinamid in Ν,Ν-Dknethylacetamid gelöst und stufenweise der abgekühlten Lösung des Chlorids der 4-Chlorbuttersiure in einem aprotischen organischen Lösungsmittel zugesetzt Der entstandene Niederschlag des Gh/cinamidsatzes der Formel V wird zur Regenerierung des Glydnamids nitriert, während das leicht flüchtige Lösungsmittel aus dem Filtrat unter vermindertem Druck entfernt wird. Das Produkt wird unter Zusatz eines geeigneten Lösungsmittels, in welchem das Produkt unlösfich ist, aus dem Ruckstand ausgefällt Das erhaltene 4-Chkwbutyrylglycinatnid wird anschließend in Alkohol gelöst und in Gegenwart von Natriumhydroxid oder eines Natriumalkoholtes, oder des basischen Anionenaustau· schers Dowex 1 in 2-Oxo-l-pyrrondin-acetamid umgewandelt, welches aus der Reaktionslosung nach Entfernen des Lösungsmittels isoliert wird.According to the invention, glycine amide is converted into Ν, Ν-Dknethylacetamid dissolved and gradually cooled down Solution of the chloride of 4-chlorobutyric acid in one aprotic organic solvent added. The resulting precipitate of Gh / cinamidatzes of Formula V is used to regenerate Glydnamide nitrated while the volatile solvent is off the filtrate is removed under reduced pressure. The product is made with the addition of a suitable Solvent in which the product is insoluble, precipitated from the residue. The 4-Chkwbutyrylglycinatnid obtained is then dissolved in alcohol and in the presence of sodium hydroxide or one Sodium alcohol, or basic anion exchange Scher's Dowex 1 converted into 2-oxo-l-pyrrondine acetamide, which from the reaction solution after Removing the solvent is isolated.

Der Vorteil des erfindungsgemifien Verfahrens besteht darin, daß die Anwendung von Natrium bzw. Natriumhydrid und das Verfahren mit dem intermediären Ammoniumsalz vermieden wird, so daß das erfindungsgemäße Verfahren einfach durchzuführen ist Ferner sind die Ausgangsstoffe leicht zugänglich.The advantage of the method according to the invention is that the use of sodium or Sodium hydride and the process with the intermediate ammonium salt is avoided, so that the The process according to the invention is easy to carry out. Furthermore, the starting materials are easily accessible.

Herstellung der Ausgangsverbindung
4-Chtorbutyrylglycinamid der Formel IV
Preparation of the starting compound
4-chlorobutyrylglycine amide of the formula IV

11,1g (0,15MoI) Glycinamid werden in 5OnU Ν,Ν-Dimethylacetamid unter leichtem Erwärmen gelöst und zu der Lösung stufenweise 10,55 g (0,075MoI) Chlorid der 4-Chk>rbuttersäure in 50 ml wasserfreiem Dioxaa tmter Bskahking zugesetzt Danach wird die Reaktionslösung noch weitere 10 Minuten bei Zimmertemperatur geröhrt end der entstandene Niederschlag filtriert Man erhält 8 g Glycinamid HCL. Das Lösungsmittel Dkwcan wird durch Destillation im Vakuum entfernt und das Produkt mit Äther aus dem Rucksund abgeschieden. Man erhält 103 g (78%) des Produktes, Fj t23 - \ 25°C11.1g (0.15MoI) glycine amide are dissolved in 5OnU Ν, Ν-dimethylacetamide with gentle warming and then 10.55 g (0.075MoI) chloride of 4-chk> rbutyric acid in 50 ml anhydrous dioxa tmter Bskahking are gradually added to the solution the reaction solution is stirred for a further 10 minutes at room temperature and the precipitate formed is filtered off. 8 g of glycinamide HCl are obtained. The Dkwcan solvent is removed by distillation in vacuo and the product is separated from the backwater using ether. This gives 103 g (78%) of product, Fj t23 - \ 25 ° C

Das Produkt zeigt im DOnnschichtchromatognunm auf SBicagel mk Methytenchlorid-Aceton-Methanol = 5:5:1 nur einen Fleck bei Rf 0,43 (Nachweis durch Besprühen mit Iod).The product shows in thin-layer chromatography on SBicagel mk methylene chloride-acetone-methanol = 5: 5: 1 only one spot at Rf 0.43 (detection by spraying with iodine).

Zu Analysenzwecken wird das Produkt aus einer Mischung von Aceton mit Hexan oder Äthylacetat umkristaffisiert, wobei farblose Plättchen erhalten werden,Fpl28-130°CFor analytical purposes, the product is made from a mixture of acetone with hexane or ethyl acetate recrystallized, giving colorless platelets be, mp 28-130 ° C

Analyse: CeHi IN2O2Cl (17$62)Analysis: CeHi IN 2 O 2 Cl (17 $ 62)

Berechnet: C 4034, H 421. N 15,68%;
gefunden: C 40,46, H 5,97, N 15,54%.
Calculated: C 4034, H 421. N 15.68%;
Found: C 40.46, H 5.97, N 15.54%.

IR-Spektrum(cm-J):IR spectrum (cm- J ):

340Θ, 3310,3200(NH2, NH),340Θ, 3310, 3200 (NH 2 , NH),

1680- 1620(C -0, prim. + sek. Amid).1680-1620 (C-0, prim. + Sec. Amide).

1550-153O(sek. Amid)1550-153O (sec. Amide)

Das erfindungsgemäße Verfahren wird anhand der folgenden Beispiele näher erläutert:The inventive method is based on the following examples are explained in more detail:

Beispiel 1example 1

2-Oxo-1 -pyrrolidin-acetamid durch Cyclisieren
von 4-Chlorbutyrylglycinamid mit NaOH.
2-Oxo-1-pyrrolidine-acetamide by cyclization
of 4-chlorobutyrylglycine amide with NaOH.

10 g (0,056 Mol) 4-Chlorbutyrylglycinamid werden unter Erwärmen bis zu 500C in 100 ml wasserfreiem Äthanol gelöst und der Lösung 5,9 ml 1 η Natriumhydroxid in Äthanol (0,056 Mol) unter Rühren tropfenweise zugefügt. Die Reaktionslösung wird 10 Minuten unter Rückflußkühlung bis zum Sieden erhitzt. Nach Abküh- ι ο lung wird das entstandene Natriumchlorid (2,9 g, 89%) durch Filtration abgetrennt Nach Entfernen des Lösungsmittels erhält man durch Zusatz von Isopropanol zum öligen Rückstand 63 g (86%) des weißen, kristallinen Produktes, Fp 145- 147°C.10 g (0.056 mol) of 4-chlorobutyrylglycine amide are dissolved in 100 ml of anhydrous ethanol with heating up to 50 ° C. and 5.9 ml of 1 η sodium hydroxide in ethanol (0.056 mol) are added dropwise with stirring. The reaction solution is refluxed for 10 minutes and heated to boiling. After cooling, the sodium chloride formed (2.9 g, 89%) is separated off by filtration. After removing the solvent, adding isopropanol to the oily residue gives 63 g (86%) of the white, crystalline product, mp 145 - 147 ° C.

Beispiel 2Example 2

2-Oxo-1 -pyrrolidin-acetamid durch Cyclisieren
mit Natrium-tert-Butylat.
2-Oxo-1-pyrrolidine-acetamide by cyclization
with sodium tert-butoxide.

1515th

2020th

4 g (0,022 MoI) 4-Chlorbutyrylglycinamid werden in 80 ml Dioxan unter Erwärmen gelöst. Zur Lösung gibt man unter Rühren eine Suspension von 0,022 Mol Natrium-tert.-Butylat in 20 ml wasserfreiem Dioxan. Die Mischung wird bei Raumtemperatur eine Stunde gerührt, der Niederschlag (1,2 g, (94%)) durch Filtration abgetrennt. Die Mutterlauge wird bis zur Trockne eingedampft und das Rohprodukt aus Isopropanol kristallisiert, wodurch 2,24 g (72%) des Produktes erhalten werden, Fp 146-149° C.4 g (0.022 mol) of 4-chlorobutyrylglycine amide are dissolved in 80 ml of dioxane with heating. A suspension of 0.022 mol of sodium tert-butoxide in 20 ml of anhydrous dioxane is added to the solution with stirring. The mixture is stirred at room temperature for one hour, and the precipitate (1.2 g, (94%)) is separated off by filtration. The mother liquor is evaporated to dryness and the crude product crystallized from isopropanol to give 2.24 g (72%) of the product, M p 146-149 ° C.

Auf analoge Weise läßt sich die Ringschlußreaktion von 4-Chlorbutyrylglycinamid mit Natriummethylat oder -äthylat durchführen.The ring closure reaction of 4-chlorobutyrylglycine amide with sodium methylate can be carried out in an analogous manner or ethylate.

Beispiel 3Example 3

2-Oxo-1-pyrrolidin-acetamid durch Cyclisieren von 4-Chlor-butyrylglycinamid unter Anwendung eines Anionenaustausch^.2-Oxo-1-pyrrolidine-acetamide by cyclizing 4-chloro-butyrylglycine amide using a Anion exchange ^.

2,2 g (0,0124MoI) 4-Chlorbutyrylglycinamid werden in 15 ml wasserfreiem Äthanol gelöst und zu einer Suspension des Ionenaustauschers Dowex 1 in Äthanol gegeben. Die Suspension enthält 2OmI des trockenen Ionenaustauschers Dowex 1 in der OH-Form in 30 ml wasserfreiem ÄthanoL Das Reaktionsgemisch wird eine Stunde bei einer Temperatur von 2O-25°C gerührt. Anschließend wird der Austauscher abdekantiert und mit 20 ml Äthanol gewaschen. Das gesamte Äthanol wird dann abgedampft Aus dem festen Rückstand erhält man durch Umkristallisation aus Isopropanol 1,25 g (71 %) des Produktes, Fp 145 -147° C.2.2 g (0.0124MoI) of 4-chlorobutyrylglycine amide will be used dissolved in 15 ml of anhydrous ethanol and to one Added suspension of the ion exchanger Dowex 1 in ethanol. The suspension contains 20mI of the dry Ion exchanger Dowex 1 in the OH form in 30 ml of anhydrous EthanoL The reaction mixture is a Stirred at a temperature of 20-25 ° C. for an hour. The exchanger is then decanted and washed with 20 ml of ethanol. All of the ethanol is then evaporated from the solid residue 1.25 g (71%) of the product are obtained by recrystallization from isopropanol, melting point 145 ° -147 ° C.

Auf analoge Weise erhält man ein wesentlich reineres Rohprodukt nach Umkristallisation aus Isopropanol in Ausbeuten von 85% mit einem Fp von 148-1500C, wenn man mit einer mit dem Austauscher gefüllten Kolonne arbeitet.In an analogous way one obtains a much purer crude product after recrystallization from isopropanol in 85% yield with a F p of 148-150 0 C, when working with a column filled with the exchanger.

Claims (1)

Patentanspruch: »Verfahren zur Herstellung von 2-Oxo-l-pyrrolidin-acetamid der FormelClaim: »Process for the preparation of 2-oxo-l-pyrrolidine acetamide of the formula CH2-CONH2 CH 2 -CONH 2 dadurch gekennzeichnet, daß man 4-Chlor-butylrylglycinamid in einem organischen Lösungsmittel löst und in Gegenwart voncharacterized in that 4-chloro-butylrylglycine amide in an organic Solvent dissolves and in the presence of eines Natriumalkoholats oder eines basischen Ionenaustauschers des Typs Dowex 1 bei einer Temperatur ab Iff C cyclisiert.«a sodium alcoholate or a basic ion exchanger of the Dowex 1 type cyclized at a temperature from Iff C. «
DE2759297A 1976-01-14 1977-01-14 Process for the preparation of 2-oxo-1-pyrrolidine-acetamide Expired DE2759297C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU7776A YU39660B (en) 1976-01-14 1976-01-14 Process for obtaining 2-oxo-1-pyrrolidine acetamide
YU198376A YU40148B (en) 1976-08-11 1976-08-11 Process for preparing n-subtituted amides of 2-oxo-pyrrolidines

Publications (2)

Publication Number Publication Date
DE2759297B1 true DE2759297B1 (en) 1979-07-19
DE2759297C2 DE2759297C2 (en) 1980-04-03

Family

ID=27130704

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2701450A Expired DE2701450C2 (en) 1976-01-14 1977-01-14 Process for the preparation of N-substituted amides of 2-oxo-1-pyrrolidine
DE2759297A Expired DE2759297C2 (en) 1976-01-14 1977-01-14 Process for the preparation of 2-oxo-1-pyrrolidine-acetamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2701450A Expired DE2701450C2 (en) 1976-01-14 1977-01-14 Process for the preparation of N-substituted amides of 2-oxo-1-pyrrolidine

Country Status (12)

Country Link
JP (1) JPS603320B2 (en)
AT (1) AT360980B (en)
CH (1) CH627742A5 (en)
DD (1) DD128591A5 (en)
DE (2) DE2701450C2 (en)
FI (1) FI66846C (en)
FR (1) FR2344535A1 (en)
GB (2) GB1549754A (en)
HU (1) HU173642B (en)
NL (1) NL7700408A (en)
PL (1) PL102996B1 (en)
SE (1) SE415972B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539817A (en) * 1976-10-22 1979-02-07 Ucb Sa N-substituted lactams
EP0115473A3 (en) * 1983-01-27 1987-01-21 Ciba-Geigy Ag Substituted pyrrolidinone derivatives and process for their preparation
EP0115472A3 (en) * 1983-01-27 1985-10-02 Ciba-Geigy Ag Pyrrolidinon derivatives and process for their preparation
IT1190378B (en) * 1985-06-21 1988-02-16 Isf Spa PYROLIDONIC DERIVATIVES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250784A (en) * 1963-12-23 1966-05-10 Gen Aniline & Film Corp Pyrrolidonyl-gamma-butyramide and process of preparing
GB1039113A (en) * 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1361388A (en) * 1970-08-05 1974-07-24 Geistlich Soehne Ag Ny--sulphamoylaryl--pyrrolidines
FR2363474A1 (en) * 1976-09-03 1978-03-31 Doris Dev Richesse Sous Marine Sea bed anchor placing system - uses hydraulic motor driven borer at end of chain which carries pairs of pivoted flukes (NO 28.3.78)

Also Published As

Publication number Publication date
DE2759297C2 (en) 1980-04-03
HU173642B (en) 1979-07-28
CH627742A5 (en) 1982-01-29
DE2701450C2 (en) 1984-10-18
FR2344535A1 (en) 1977-10-14
NL7700408A (en) 1977-07-18
DE2701450A1 (en) 1977-07-21
JPS52116462A (en) 1977-09-29
AT360980B (en) 1981-02-10
DD128591A5 (en) 1977-11-30
FI770087A (en) 1977-07-15
JPS603320B2 (en) 1985-01-26
SE7700173L (en) 1977-07-15
PL195311A1 (en) 1978-02-27
SE415972B (en) 1980-11-17
FR2344535B1 (en) 1982-10-08
PL102996B1 (en) 1979-05-31
FI66846C (en) 1984-12-10
GB1549755A (en) 1979-08-08
FI66846B (en) 1984-08-31
GB1549754A (en) 1979-08-08
ATA4377A (en) 1979-07-15

Similar Documents

Publication Publication Date Title
DE2560398C2 (en) 2-Amino-thiazol-4-yl-acetic acid derivatives and processes for their preparation
AT376977B (en) METHOD FOR PRODUCING NEW 5-SUBSTITUTED OXAZOLIDIN-2,4-DIONES AND THEIR SALTS
DE1620694B2 (en) Process for the preparation of 5-methyl-7-diethylamino-s-triazolo [1,5-a] pyrimidine and its salts with acids
DE1593723A1 (en) Process for the production of acetals
DE2851028C2 (en)
DE2759297B1 (en) Process for the preparation of 2-oxo-1-pyrrolidine-acetamide
CH412889A (en) Process for the preparation of 2-methyl-3-oxypyridines
DE3872956T2 (en) METHOD FOR PRODUCING 2,4-DIAMINO-6- (1-PIPERIDINYL) -PYRAMIDIN-N-OXIDE.
DE2420474B2 (en) PROCESS FOR THE PRODUCTION OF BENZOINE ETHERS
DD142876A5 (en) PROCESS FOR THE PREPARATION OF PYRROLIDINCARBOXALDEHYDE AND PIPERIDINCARBOXALDEHYDE DERIVATIVES
DE2661028C2 (en)
DE2065698C3 (en) Process for the preparation of 2-isopropyl-6-methyl-4 (3H) -pyrimidone
DE2122070A1 (en) 1 Veratryl 4 methyl 5 ethyl 7,8 dimethoxy 2,3 diazabicyclo square brackets to 5,4,0 square brackets to undeca pentaen (1,3,6,8,10) and its use
DE3135840C1 (en) 2-Azido-3-benzyloxy-propionic acid benzyl ester and process for its preparation
EP0159640A1 (en) 4-Methoxy-2,2'-bipyridyl-6-aldoximes, process and intermediates for their preparation and their use as medicines
DD231073A1 (en) PROCESS FOR PREPARING NEW AZABICYCLO (3.3.1) NONAN DERIVATIVES
CH650006A5 (en) Process for the preparation of 5-fluorouracil derivatives
DE19647538A1 (en) N-Substituted 2,2-di:phenyl-acetamide enantiomer preparation
AT214928B (en) Process for the preparation of new camphidinium compounds
AT371448B (en) METHOD FOR PRODUCING NEW CIS-4A-PHENYL-ISOCHINOLINE DERIVATIVES AND THEIR ACID ADDITION SALTS
AT356291B (en) METHOD FOR THE PRODUCTION OF COMPOUNDS IN THE DIHYDROLYSERIC ACID AND DIHYDROISOLYER SERIES
AT372945B (en) METHOD FOR PRODUCING NEW NSUBSTITUTED MORANOLINE DERIVATIVES
DE3382642T2 (en) METHOD OF PRODUCING DERIVATIVES OF 3,5-DIOXOCYCLOHEXANCARBONIC ACID.
AT223197B (en) Process for the preparation of new esters of N- (β-oxyethyl) -N '- [γ- (3'-chloro-10'-phenthiazinyl) -propyl] -piperazine
AT244344B (en) Process for the preparation of new pyrimidine compounds

Legal Events

Date Code Title Description
OI Miscellaneous see part 1
OI Miscellaneous see part 1
OD Request for examination
8328 Change in the person/name/address of the agent

Free format text: VON FUENER, A., DIPL.-CHEM. DR.RER.NAT. EBBINGHAUS, D., DIPL.-ING. FINCK, K., DIPL.-ING. DR.-ING., PAT.-ANW., 8000 MUENCHEN

8339 Ceased/non-payment of the annual fee